- Home
- GMM vs ACHV Comparison
GMM vs ACHV Comparison
Compare GMM & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- ACHV
- Stock Information
- Founded
- GMM 2017
- ACHV N/A
- Country
- GMM China
- ACHV Canada
- Employees
- GMM N/A
- ACHV N/A
- Industry
- GMM
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GMM
- ACHV Health Care
- Exchange
- GMM Nasdaq
- ACHV Nasdaq
- Market Cap
- GMM 70.8M
- ACHV 72.5M
- IPO Year
- GMM 2023
- ACHV N/A
- Fundamental
- Price
- GMM $2.79
- ACHV $3.80
- Analyst Decision
- GMM
- ACHV Strong Buy
- Analyst Count
- GMM 0
- ACHV 3
- Target Price
- GMM N/A
- ACHV $14.33
- AVG Volume (30 Days)
- GMM 25.2K
- ACHV 234.9K
- Earning Date
- GMM 06-10-2025
- ACHV 05-13-2025
- Dividend Yield
- GMM N/A
- ACHV N/A
- EPS Growth
- GMM 62.17
- ACHV N/A
- EPS
- GMM 6.37
- ACHV N/A
- Revenue
- GMM $41,360,953.00
- ACHV N/A
- Revenue This Year
- GMM N/A
- ACHV N/A
- Revenue Next Year
- GMM N/A
- ACHV N/A
- P/E Ratio
- GMM $0.44
- ACHV N/A
- Revenue Growth
- GMM 53.82
- ACHV N/A
- 52 Week Low
- GMM $1.69
- ACHV $1.84
- 52 Week High
- GMM $15.60
- ACHV $5.58
- Technical
- Relative Strength Index (RSI)
- GMM 51.23
- ACHV 70.30
- Support Level
- GMM $2.64
- ACHV $2.89
- Resistance Level
- GMM $2.99
- ACHV $3.32
- Average True Range (ATR)
- GMM 0.31
- ACHV 0.25
- MACD
- GMM 0.02
- ACHV 0.07
- Stochastic Oscillator
- GMM 51.72
- ACHV 91.47
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.